 we report on our first quarter 2023 financial results and discuss our plans for the future as we move into the second half of the year. 
 we also discuss the status of our ongoing clinical studies including the recently reported positive top line results from the first randomized placebo-controlled trial for nicotine e-cigarette cessation in the first quarter of 2023.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in    # 1#2#3#4#1 * # 2 *, # 3 ( # 4 )    # 1#2#3@xmath0 # 1#2#3@xmath1 # 1#2#3@xmath2 # 1#2#3@xmath3 # 1#2#3@xmath4 # 1#2#3@xmath5 # 1#2#3@xmath6 # 1#2#3@xmath7 # 1#2#3@xmath8 # 1#2#3@xmath9 # 1#2#3@xmath10 # 1#2#3@xmath11 # 1#2#3@xmath12 # 1#2#3@xmath13 # 1#2#3@xmath14 # 1#2#3@xmath15 # 1#2#3@xmath16 # 1#2#3@xmath17 # 1#2#3@xmath18 # 1#2#3@xmath19 # 1#2#3@xmath20 # 1#2#3@xmath21 # 1#2#3@xmath22 # 1#2#3@xmath23 # 1#2#3@xmath24 # 1#2#3@xmath25 # 1#2#3@xmath26 # 1#2#3@xmath27 # 1#2#3@xmath28 # 1#2#3@xmath29 # 1#2#3@xmath40 # 1#2#3@xmath51 # 1#2#3@xmath60 # 1#2#3@xmath61 # 1#2#3@xmath70 # 1#2#3@xmath71 # 1#2#3@xmath72 # 1#2#3@xmath73 # 1#2#3@xmath74     #